The study of Henoch-Schonleinpurpura (HSP) in children was reviewed in terms of epidemiology, etiology and pathogenesis, clinical manifestations, auxiliary examination, diagnostic criteria, treatment methods, prognosis and follow-up. Existing studies had fully demonstrated that, the etiology and pathogenesis of HSP werenot clear, and the mechanism of immune and genetic actionstill needs to be further studied. There is lack of specific means of clinical examination, so the diagnosis of HSP in children mainly depends on the symptoms and signs. The histopathological analysis of the patients is especially important when there are rare or uncommon clinical manifestations. At present, there is no unified and specific treatment plan of HSP at home and abroad. Most of the patients with mild illness were treated symptomatically, and most of the patients with severe illness were treated individually with hormone. However, large sample size, multi-center Randomized Controlled Trial (RTC) studies, and evidence-based medical validation are needed for relevant treatment plan of HSP. The short-term prognosis of HSP is better, and the long-term prognosis is mainly related to renal involvement. The key to reduce renal involvement lies in early detection, early diagnosis and early treatment.